Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD.

Gynecol Oncol. 2008 Jun;109(3):323-8. doi: 10.1016/j.ygyno.2008.02.024. Epub 2008 Apr 18.

2.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML.

J Clin Oncol. 2007 Jul 1;25(19):2755-63. Erratum in: J Clin Oncol. 2007 Aug 20;25(24):3790.

PMID:
17602081
3.

Soft tissue sarcoma.

Demetri GD, Baker LH, Benjamin RS, Casper ES, Conrad EU 3rd, D'Amato GZ, DeLaney TF, Ettinger DS, Heck R Jr, Heslin MJ, Hutchinson RJ, Jacobs CD, Kiel K, Kraybill WG, Letson GD, O'Donnell RJ, Paz IB, Pfeifer J, Pollock RE, Randall RL, Sasson AR, Schupak KD, Tyler DS, von Mehren M, Wayne J; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2007 Apr;5(4):364-99. No abstract available.

PMID:
17442230
4.
5.

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD; Gynecologic Oncology Group..

Gynecol Oncol. 2007 May;105(2):508-16. Epub 2007 Feb 15.

6.

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.

Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, van Boven HH, Schellens JH, Rodenhuis S.

Invest New Drugs. 2007 Jun;25(3):279-81. Epub 2007 Jan 13. No abstract available.

PMID:
17221305
7.

Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project.

Belknap SM, Kuzel TM, Yarnold PR, Slimack N, Lyons EA, Raisch DW, Bennett CL.

Cancer. 2006 May 1;106(9):2051-7.

8.

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Penel N, Blay JY; Groupe Sarcome Fran├žais..

Int J Cancer. 2006 Aug 1;119(3):706-11. Erratum in: Int J Cancer. 2007 Jan 15;120(2):450. Penel, Nicolas [added].

9.

A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.

Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J; Spanish Group for Research on Sarcomas..

Cancer. 2005 Oct 15;104(8):1706-12.

10.

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD.

J Clin Oncol. 2005 Aug 20;23(24):5484-92.

PMID:
16110008
11.

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of soft tissue sarcomas.

Leyvraz S, Jelic S; ESMO Guidelines Task Force..

Ann Oncol. 2005;16 Suppl 1:i69-70. No abstract available.

PMID:
15888762
12.

High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.

Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, Agelaki S, Malas K, Bozionelou V, Georgoulias V.

Lung Cancer. 2004 Jun;44(3):363-8.

PMID:
15140550
13.

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.

Look KY, Sandler A, Blessing JA, Lucci JA 3rd, Rose PG; Gynecologic Oncology Group (GOG) Study..

Gynecol Oncol. 2004 Feb;92(2):644-7.

PMID:
14766260
14.

Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.

Gallup DG, Blessing JA, Andersen W, Morgan MA; Gynecologic Oncology Group Study..

Gynecol Oncol. 2003 Apr;89(1):48-51.

PMID:
12694653
15.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR.

J Clin Oncol. 2002 Jun 15;20(12):2824-31.

PMID:
12065559
16.

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.

Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group..

Eur J Cancer. 2002 Mar;38(4):543-9.

PMID:
11872347
17.
18.

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E.

J Clin Oncol. 2001 Mar 1;19(5):1248-55.

PMID:
11230465
19.

Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.

Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L.

Am J Clin Oncol. 2000 Aug;23(4):355-7.

PMID:
10955863
20.

Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.

Sutton G, Blessing JA, Ball H.

Gynecol Oncol. 1999 Sep;74(3):346-9.

PMID:
10479491

Supplemental Content

Support Center